CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Core Insights - CRISPR Therapeutics will present at the Jefferies London Healthcare Conference on November 20, 2024, at 4:00 p.m. GMT [1] - A live webcast of the presentation will be available on the company's website, with a replay archived for 14 days [2] Company Overview - CRISPR Therapeutics has evolved from a research-stage company to a leader in gene-based medicines, recently achieving the historic approval of the first CRISPR-based therapy [3] - The company has a diverse portfolio targeting various diseases, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases [3] - The first CRISPR/Cas9 gene-edited therapy was advanced into clinical trials in 2018 for sickle cell disease and beta thalassemia, with CASGEVY (exa-cel) approved in some countries starting late 2023 [3] - CRISPR Therapeutics has established strategic partnerships with Bayer and Vertex Pharmaceuticals to enhance its research and development efforts [3] - The company is headquartered in Zug, Switzerland, with R&D operations in Boston and San Francisco, and business offices in London [3]